Medical Doctor Program year 2019 Source: CMS Open Payments, 2026 publication

Linda Moghtader

Psychosomatic Medicine Los Angeles, CA Medical Doctor

NPI 1497963722 CMS profile 295342

12300 Wilshire Blvd, Suite 330, Los Angeles, CA 90025

Open in the dashboard

General payments

$49

1 record reported · program year 2019

Research payments

$0

Paid to them · None reported · program year 2019

Ownership & investment interest

$0

None reported

Through program year 2019, Linda Moghtader of Los Angeles, CA is reported in the CMS Open Payments database as having received $49 across 1 general payment and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 18th percentile of Psychosomatic Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2019 General $49 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Linda Moghtader
  • Psychosomatic Medicine median
  • Middle half of Psychosomatic Medicine
  • National median

In program year 2025, general payments to Linda Moghtader were reported at $0. Among 72 Psychosomatic Medicine profiles paid that year, the median was $152 and the middle half received between $47 and $428.

Show as a table
Year Linda Moghtader Psychosomatic Medicine median Middle half National median
2019 $49 $125 $51–$524 $163
2020 $0 $117 $29–$251 $114
2021 $0 $123 $33–$366 $132
2022 $0 $107 $37–$450 $149
2023 $0 $131 $57–$397 $160
2024 $0 $122 $27–$293 $164
2025 $0 $152 $47–$428 $169

Breakdown

Who paid General payments · program year 2019
  1. Janssen Pharmaceuticals, Inc $49 1 payment

Every payment, record by record

What the payments were for General payments · program year 2019
  1. Food and Beverage $49 1 payment
Products named General payments · program year 2019
  1. SPRAVATO $49 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,003

Median for Neuropsychiatry: 88

Drug cost

$24,672

Median for Neuropsychiatry: $2,689

Branded share of claims

35.7%

Median for Neuropsychiatry: 16.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belsomra Suvorexant Brand 12 $5,217
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 53 $3,330
Bupropion Xl Bupropion Hcl Brand 134 $2,803
Venlafaxine Hcl Er Venlafaxine Hcl Brand 67 $2,642
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 37 $2,348
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 22 $1,333
Escitalopram Oxalate Generic 88 $1,031
Aripiprazole Generic 12 $647
Trazodone Hcl Generic 62 $554
Sertraline Hcl Generic 63 $543

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.

Records

1 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychosomatic Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2019

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record